DK3331877T3 - Pyrazolpyrimidinderivat og anvendelser deraf - Google Patents
Pyrazolpyrimidinderivat og anvendelser deraf Download PDFInfo
- Publication number
- DK3331877T3 DK3331877T3 DK16753709.1T DK16753709T DK3331877T3 DK 3331877 T3 DK3331877 T3 DK 3331877T3 DK 16753709 T DK16753709 T DK 16753709T DK 3331877 T3 DK3331877 T3 DK 3331877T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrimidine derivative
- pyrazole pyrimidine
- pyrazole
- derivative
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3331877T3 true DK3331877T3 (da) | 2022-01-03 |
Family
ID=56738143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16753709.1T DK3331877T3 (da) | 2015-08-04 | 2016-08-04 | Pyrazolpyrimidinderivat og anvendelser deraf |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10376511B2 (da) |
| EP (1) | EP3331877B1 (da) |
| JP (1) | JP7083309B2 (da) |
| KR (1) | KR102698366B1 (da) |
| CN (1) | CN108137562B (da) |
| AU (2) | AU2016304464B2 (da) |
| CA (1) | CA2994644A1 (da) |
| CY (1) | CY1124898T1 (da) |
| DK (1) | DK3331877T3 (da) |
| ES (1) | ES2901349T3 (da) |
| HK (1) | HK1256535A1 (da) |
| HR (1) | HRP20211949T1 (da) |
| HU (1) | HUE057607T2 (da) |
| IL (1) | IL257282B (da) |
| LT (1) | LT3331877T (da) |
| MX (1) | MX2018001395A (da) |
| PL (1) | PL3331877T3 (da) |
| PT (1) | PT3331877T (da) |
| RS (1) | RS62728B1 (da) |
| RU (1) | RU2735522C2 (da) |
| SI (1) | SI3331877T1 (da) |
| SM (1) | SMT202100720T1 (da) |
| WO (1) | WO2017021969A1 (da) |
| ZA (1) | ZA201800671B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2901349T3 (es) * | 2015-08-04 | 2022-03-22 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivado de pirazol pirimidina y usos del mismo |
| EP3577108B1 (en) | 2017-02-01 | 2021-10-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or irak1 inhibitors for treating cancer |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| JP2021512922A (ja) * | 2018-02-08 | 2021-05-20 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用 |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| EP3976600A1 (en) * | 2019-06-03 | 2022-04-06 | Biotheryx, Inc. | Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof |
| CN114127058B (zh) * | 2019-07-04 | 2024-06-25 | 深圳国顺康医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| AU2020328025A1 (en) | 2019-08-14 | 2022-03-03 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| CA3162434A1 (en) * | 2020-01-13 | 2021-07-22 | Kyle W.H. Chan | Pyrazolylpyrimidines and use thereof |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| EP4313053A4 (en) * | 2021-03-24 | 2025-03-05 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | PYRAZOLYLPYRIMIDINES FOR THE TREATMENT OF MALIGNANT SOLID TUMOR |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) * | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407132T1 (de) | 2000-12-05 | 2008-09-15 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| WO2002092573A2 (en) * | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| ZA200607639B (en) | 2004-03-30 | 2008-05-28 | Taisho Pharmaceutical Co Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| JP2007145819A (ja) | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| US20100063049A1 (en) | 2006-05-26 | 2010-03-11 | Clifford Jones | 2-carbocycloamino-4-imidazolylpyrimidines as agents for the inhbition of cell proliferation |
| EA018459B1 (ru) | 2007-12-07 | 2013-08-30 | Новартис Аг | Производные пиразола и их применение в качестве ингибиторов циклинзависимых киназ |
| CA2853454C (en) | 2011-11-04 | 2020-01-21 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| MX2016003843A (es) | 2013-09-27 | 2017-02-15 | Nimbus Iris Inc | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. |
| JP6491202B2 (ja) * | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| ES2901349T3 (es) | 2015-08-04 | 2022-03-22 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivado de pirazol pirimidina y usos del mismo |
| EP3577108B1 (en) * | 2017-02-01 | 2021-10-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or irak1 inhibitors for treating cancer |
| JP2021512922A (ja) | 2018-02-08 | 2021-05-20 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用 |
-
2016
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 SM SM20210720T patent/SMT202100720T1/it unknown
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 KR KR1020187006128A patent/KR102698366B1/ko active Active
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
- 2016-08-04 MX MX2018001395A patent/MX2018001395A/es unknown
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en active Application Filing
-
2018
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
- 2018-12-05 HK HK18115603.7A patent/HK1256535A1/zh unknown
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
-
2024
- 2024-02-05 US US18/432,931 patent/US20250049793A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3331877T3 (da) | Pyrazolpyrimidinderivat og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| LT3386323T (lt) | Asmeninis garinimo prietaisas | |
| SI3310982T1 (sl) | Pohištveni šarnir | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| IL265166B (en) | Anti-influenza virus pyrimidine derivatives | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
| DK3269809T3 (da) | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DE112015003841A5 (de) | Di- und triphosphat-propharmaka | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
| EP3372589A4 (en) | pyrimidine derivative | |
| DK3180335T3 (da) | Cytokrom-p450-inhibitorer og anvendelser deraf | |
| DK3380465T3 (da) | Diaminopyridinderivativer | |
| DK3263133T3 (da) | Pyridinonforbindelse og anvendelse deraf |